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Objective: To assess herpes simplex virus type 1 (HSV-1) epidemiology in Africa. 
Methods: This systematic review was conducted per the Cochrane Collaboration guidelines. Findings 
were reported following the PRISMA guidelines. Research questions were addressed using random-effects 
meta-analyses and meta-regressions. 
Results: Forty-three overall (and 69 stratiﬁed) HSV-1 seroprevalence measures, and 18 and eight propor- 
tions of HSV-1 viral detection in genital ulcer disease (GUD) and in genital herpes, respectively, were ex- 
tracted from 37 reports. Pooled mean seroprevalence was 67.1% (95% conﬁdence interval (CI): 54.7–78.5%) 
in children, and 96.2% (95% CI: 95.0–97.3%) in adults. Across age groups, pooled mean was 44.4% (95% CI: 
29.9–59.3%) in ≤5 years-old, 85.6% (95% CI: 81.0–89.6%) in 6–15 years-old, 93.3% (95% CI: 89.2–96.6%) in 
16–25 years-old, and 93.8% (95% CI: 84.6–99.4%) in > 25 years-old. Age explained 78.8% of seroprevalence 
variation. Pooled mean proportion of HSV-1 detection was 0.4% (95% CI: 0.0–1.5%) in GUD, and 1.2% (95% 
CI: 0.0–4.0%) in genital herpes. 
Conclusions: HSV-1 is universally prevalent in Africa, at higher levels than other regions, with no evidence 
for declines in seroprevalence in recent decades. Nearly every person acquires the infection in childhood 
through oral-to-oral transmission, before sexual debut. Sexual oral-to-genital and genital-to-genital trans- 
mission appear very limited. 
© 2019 The Author(s). Published by Elsevier Ltd on behalf of The British Infection Association. 
This is an open access article under the CC BY-NC-ND license. 
( http://creativecommons.org/licenses/by-nc-nd/4.0/ ) 
Introduction 
Herpes simplex virus type 1 (HSV-1) is endemic worldwide. 1 
The virus is predominantly acquired and transmitted orally leading 
to a lifelong infection. 2,3 Infection with HSV-1 is the underlying 
cause of multiple diseases, though the most common clinical 
manifestation is that of oral herpes. 2–4 HSV-1 acquisition usually 
occurs in childhood, well before sexual debut, where proximity to 
parents and other family members, as well as to peers, increases 
the likelihood of exposure and transmission. 2,4 Development of an 
HSV-1 vaccine is a focus of ongoing international multi-sectorial 
effort, led in part by the World Health Organization (WHO). 5,6 
∗ Corresponding author at: Infectious Disease Epidemiology Group, Weill Cor- 
nell Medicine-Qatar, Cornell University, Qatar Foundation - Education City, P.O. Box 
24144, Doha, Qatar. 
E-mail address: lja2002@qatar-med.cornell.edu (L.J. Abu-Raddad). 
Mounting evidence from Western countries, 2,7–14 Asia, 15 and 
Latin America and the Caribbean 16 suggests that HSV-1 is increas- 
ingly acquired genitally, and less so orally. Indeed, in several coun- 
tries, HSV-1 is already the primary cause of genital herpes. 2,17–21 
This remarkable epidemiological transition appears to be driven 
by a progressively decreasing exposure in childhood—a large frac- 
tion of youth are ﬁrst exposed to the virus genitally through oral 
sex. 2,14,21 The extent to which this transition is occurring globally, 
beyond Western, Asian, and Latin American and Caribbean coun- 
tries, remains unknown. 
This study aimed to provide a comprehensive understanding of 
HSV-1 epidemiology in Africa by systematically reviewing and syn- 
thesizing available epidemiological data on HSV-1 infection, esti- 
mating HSV-1 antibody prevalence (seroprevalence) levels in differ- 
ent population strata, assessing associations with seroprevalence, 
and estimating the role of HSV-1 in the etiology of clinically- 
diagnosed genital ulcer disease (GUD) and clinically-diagnosed 
genital herpes. 
https://doi.org/10.1016/j.jinf.2019.07.012 
0163-4453/© 2019 The Author(s). Published by Elsevier Ltd on behalf of The British Infection Association. This is an open access article under the CC BY-NC-ND license. 
( http://creativecommons.org/licenses/by-nc-nd/4.0/ ) 
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Materials and methods 
The methodology for this study follows and adapts that devel- 
oped recently to investigate HSV-1 epidemiology in Asia. 15 
Data sources and search strategy 
The systematic review was conducted with guidance of the 
Cochrane Collaboration Handbook. 22 The ﬁndings were reported 
following the Preferred Reporting Items for Systematic Reviews 
and Meta-analyses (PRISMA) guidelines (checklist in Supplemen- 
tary Table 1). 23 
The systematic literature search was performed up to July 30, 
2018, in PubMed, Embase, and African Index Medicus databases. 
The search strategies included exploded MeSH/Emtree terms as 
well as broad keywords and were not restricted by language or 
year (Supplementary Box 1). The deﬁnition for the African re- 
gion included 45 countries, and was based on the WHO deﬁnition 
for this region. 24 Included countries are found in Supplementary 
Box 2. 
Study selection and eligibility criteria 
Study selection was conducted in Endnote, a reference manager. 
Screening of studies was performed in four stages: duplicate re- 
ports identiﬁcation and removal; title and abstract screening for 
relevant and potentially relevant reports; full-text screening for rel- 
evant and potentially relevant reports; and screening of bibliogra- 
phies of relevant reports and reviews for any additional relevant 
publications. 
Inclusion criteria encompassed any report documenting pri- 
mary data on any of the following HSV-1 epidemiological outcome 
measures: (1) HSV-1 seroprevalence, (2) proportion of HSV-1 
detection in GUD, or (3) proportion of HSV-1 detection in genital 
herpes. Only HSV-1 seroprevalence measures based on quality 
type-speciﬁc (glycoprotein G-based) assays were included. Mea- 
sures of HSV-1 detection in GUD or genital herpes were based 
on detecting, isolating, and typing of the virus using genital 
ulcer swabs collected from clinically-diagnosed patients with 
GUD and/or genital herpes. Only measures including at least 10 
participants were considered. 
The following types of records were excluded: case reports, case 
series, reviews, editorials, letters-to-editors, commentaries, quali- 
tative studies, and animal studies. Studies reporting HSV-1 sero- 
prevalence in infants ( < 3 months of age) were also excluded be- 
cause of maternal antibodies. 
In this article, a “report” is a publication comprising a rele- 
vant HSV-1 outcome measure. A “study” refers to all details of one 
speciﬁc outcome measure. One report may include several studies. 
Multiple reports of the same dataset were identiﬁed as duplicates 
and deemed as one study. 
Data extraction and synthesis 
Data from relevant reports were double extracted by MH and 
HC. Among the extracted variables are publication details, study 
design and sampling methodology, study population characteris- 
tics, and HSV-1 epidemiological outcome measures. A detailed list 
of extracted variables is in Supplementary Box 3. 
Extracted HSV-1 outcome measures were replaced by their 
strata, whenever the stratum subsample size was ≥10. The strat- 
iﬁcation hierarchy for HSV-1 seroprevalence was population type, 
age bracket ( ≤15 years of age (children) versus > 15 years of age 
(adults)), and age group ( ≤5, 6–15, 16–25, and > 25 years of age). 
These age stratiﬁcations were informed by epidemiological rele- 
vance and actual available extracted data. 
The population-type stratiﬁcation was based on the following 
criteria: (1) healthy general populations including populations with 
no or minor disease conditions; (2) clinical populations including 
populations with serious disease conditions or morbidities; and (3) 
other populations including mixed-health status populations and 
populations with potentially different (or unknown) exposure level 
to HSV-1 infection than the other two categories (HIV patients and 
female sex workers, among others). 
The stratiﬁcation hierarchy for the proportions of HSV-1 detec- 
tion in GUD and in genital herpes included only primary versus re- 
current episode and study site (sexually transmitted infection (STI) 
clinic versus hospital). 
Meta-analyses 
The pooled mean HSV-1 seroprevalence was estimated, for each 
population type, age bracket, and age group, using DerSimonian- 
Laird random-effects models with inverse variance weighting, 25 
provided ≥3 outcome measures for each stratum were available. 
This meta-analysis methodology takes into account sampling varia- 
tion and heterogeneity in effect sizes (here HSV-1 seroprevalence). 
The variance of each seroprevalence measure was stabilized using 
the Freeman-Tukey arcsine square-root transformation. 26 The same 
statistical method was applied to estimate the pooled mean pro- 
portions of HSV-1 detection in GUD and in genital herpes. 
Existence of heterogeneity was assessed using the Cochran’s Q 
statistic ( p -value < 0.1 indicated strong evidence for heterogene- 
ity). 25,27 Extent of between-study variation, due to true difference 
in prevalence across studies and not chance, was calculated using 
the I 2 measure. 25 Distribution of true prevalence measures around 
the pooled mean was estimated using prediction intervals. 25,28 
Meta-analyses were conducted in R version 3.4.1 29 using the 
meta package. 30 
Meta-regressions 
Factors associated with higher HSV-1 seroprevalence and 
sources of between-study heterogeneity were investigated using 
random-effects meta-regression analyses (by regressing the log- 
transformed seroprevalence proportions). In the univariable anal- 
yses, variables with a p -value ≤0.1 qualiﬁed for inclusion in the 
multivariable analyses. In the multivariable analyses, a p -value 
≤0.05 constituted strong evidence for an association. 
The investigated factors were set a priori and included: age 
bracket, age group, assay type (Western blot, enzyme-linked im- 
munosorbent assay (ELISA), and neutralizing antibodies assay 
(NAb)), country’s income, population type, response rate ( ≥80% 
versus otherwise), sample size ( < 100 versus ≥100), sampling 
methodology (probability-based sampling versus non-probability 
sampling), sex, year of data collection, and year of publication. 
The country’s income variable followed the World Bank classi- 
ﬁcation. 31 Accordingly, countries with available HSV-1 data were 
classiﬁed as: low-income countries (Central African Republic, Er- 
itrea, Ethiopia, Mali, Uganda, United Republic of Tanzania, and Zim- 
babwe), lower-middle-income countries (Kenya, Lesotho, and Nige- 
ria), upper-middle-income countries (South Africa), and mixed for 
studies including samples from different countries. 
For the year of data collection, missing values were imputed us- 
ing the year of publication adjusted for the median difference with 
the year of data collection, for studies with available data. 
Meta-regressions were conducted in Stata/SE version 13 32 using 
the metareg package. 33 
Please cite this article as: M. Harfouche, H. Chemaitelly and L.J. Abu-Raddad, Herpes simplex virus type 1 epidemiology in Africa: Sys- 
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Fig. 1. Flow chart of article selection for the systematic review of HSV-1 infection in Africa, per the PRISMA guidelines. 23 
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Table 1 
Studies reporting HSV-1 seroprevalence in Africa. 
Author, year Year(s) of data 
collection 
Country Study site Study 
design 
Sampling 
methodology 
Population HSV-1 serological 
assay 
Sample 
size 
HSV-1 
seroprevalence (%) 
Healthy children populations ( n = 16) 
Ghebrekian, 1999 45 1995–95 Eritrea Outpatient clinic CS Conv 5–12 years old children ELISA 84 97.0 
Ghebrekian, 1999 45 1995–95 Eritrea Outpatient clinic CS Conv 1–5 years old children ELISA 54 59.0 
Johnson, 1981 46 – Nigeria Hospital CC a Conv 1–4 years old children NAb 64 26.0 
Kasubi, 2006 47 – Tanzania Outpatient clinic CS Conv 1–4 years old children ELISA 101 73.0 
Kasubi, 2006 47 – Tanzania Outpatient clinic CS Conv 5–8 years old children ELISA 111 83.8 
Kasubi, 2006 47 – Tanzania Outpatient clinic CS Conv 9–12 years old children ELISA 123 85.4 
LeGoff, 2011 48 – Central African Republic Outpatient clinic CS Conv < 5 years old children ELISA 73 58.9 
LeGoff, 2011 48 – Central African Republic Outpatient clinic CS Conv 6–10 years old children ELISA 70 88.0 
LeGoff, 2011 48 – Central African Republic Outpatient clinic CS Conv 11–15 years old children ELISA 39 90.0 
Sogbetun, 1979 49 – Nigeria Outpatient clinic CS Conv 4–11 months old babies NAb 29 6.9 
Sogbetun, 1979 49 – Nigeria Community CS Conv 1–2 years old children NAb 64 26.6 
Sogbetun, 1979 49 – Nigeria Community CS Conv 3–5 years old children NAb 64 56.3 
Sogbetun, 1979 49 – Nigeria Community CS Conv 6–10 years old children NAb 49 75.5 
Sogbetun, 1979 49 – Nigeria Community CS Conv 11–15 years old children NAb 82 82.9 
Wagner, 1994 50 1989 Uganda Community CS Conv < 9 years old children WB 14 78.6 
Wagner, 1994 50 1989 Uganda Community CS Conv 10–14 years old children WB 31 90.3 
Healthy adult populations ( n = 28) 
Ashley-Morrow, 2004 34 2000–01 Nigeria Community CS Conv > 15 years old women WB 100 100 
Ghebrekian, 1999 45 1995–95 Eritrea Community CS Conv Guerilla ﬁghters ELISA 73 88.0 
Ghebrekian, 1999 45 1995–95 Eritrea Community CS RS Truck drivers ELISA 53 85.0 
Ghebrekian, 1999 45 1995–95 Eritrea Community CS RS Port workers ELISA 48 92.0 
Ghebrekian, 1999 45 1995–95 Eritrea Outpatient clinic CS Conv Rashaida tribe individuals ELISA 45 84.0 
Ghebrekian, 1999 45 1995–95 Eritrea Outpatient clinic CS Conv Pregnant women ELISA 113 97.0 
Gwanzura, 1998 51 – Zimbabwe Community CS Conv Male factory workers WB 191 100 
Hogrefe, 2002 52 1989 Uganda Community CS RS Healthy women WB 227 100 
Hogrefe, 2002 52 – South Africa Community CS RS Healthy individuals WB 150 89.0 
Kasubi, 2006 47 – Tanzania Outpatient clinic CS Conv 17–20 years old adults ELISA 130 92.0 
LeGoff, 2011 48 – Central African Republic Outpatient clinic CS Conv 16–17 years old adults ELISA 18 100 
Leutscher, 2005 53 2002 Madagascar Community CS Conv Healthy women WB 333 95.0 
Leutscher, 2005 53 2002 Madagascar Community CS Conv Healthy men WB 310 98.0 
Marrazzo, 2013 54 2009–11 South Africa, Uganda, Zimbabwe Community RCT b Conv Healthy women ELISA 4996 95.0 
Mihret, 2002 55 1996–96 Ethiopia Community CS Conv > 15 years old women WB 243 94.7 
Mihret, 2002 55 1996–96 Ethiopia Community CS Conv > 15 years old men WB 263 92.8 
Nakku-joloba, 2014 56 2004–04 Uganda Community CS MSC 15–65 years old adults ELISA 1124 98.0 
Neal, 2011 57 – Uganda Community CS Conv Healthy adults WB 415 93.0 
Patnaik, 2007 58 1985–97 Mali Community CS Conv Middle-aged women WB 90 93.3 
Perti, 2014 59 – South Africa Hospital CS Conv Pregnant women WB 255 99.2 
( continued on next page ) 
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Table 1 ( continued ) 
Author, year Year(s) of data 
collection 
Country Study site Study 
design 
Sampling 
methodology 
Population HSV-1 serological 
assay 
Sample 
size 
HSV-1 
seroprevalence (%) 
Sogbetun, 1979 49 – Nigeria Community CS Conv 16–20 years old adults NAb 82 70.7 
Tedla, 2011 60 2002 Ethiopia Community CC a RS 15–49 years old adults ELISA 80 100 
Wagner, 1994 50 1989 Uganda Community CS Conv 15–19 years old adults WB 39 94.9 
Wagner, 1994 50 1989 Uganda Community CS Conv 20–24 years old adults WB 31 93.5 
Wagner, 1994 50 1989 Uganda Community CS Conv 25–29 years old adults WB 29 96.6 
Wagner, 1994 50 1989 Uganda Community CS Conv 30–34 years old adults WB 17 100 
Wagner, 1994 50 1989 Uganda Community CS Conv 35–39 years old adults WB 16 93.8 
Wagner, 1994 50 1989 Uganda Community CS Conv > 40 years old adults WB 83 84.3 
Healthy age-mixed populations ( n = 1) 
Kasubi, 2006 47 – Tanzania Outpatient clinic CS Conv 13–16 years old children ELISA 100 84.0 
Clinical children populations ( n = 2) 
Johnson, 1981 46 – Nigeria Hospital CC a Conv Children with marasmus NAb 16 44.0 
Johnson, 1981 46 – Nigeria Hospital CC a Conv Children with kwashiorkor NAb 37 51.0 
Clinical adult populations ( n = 12) 
Chen, 2000 61 1993–94 South Africa Outpatient clinic CS Conv Men with GUD WB 558 98.2 
Chen, 2000 61 1993–94 South Africa Outpatient clinic CS Conv Men with urethritis WB 603 98.7 
Hogrefe, 2002 52 – Zimbabwe Outpatient clinic CS RS Women in an STD clinic WB 174 95.0 
LeGoff, 2008 62 – Ghana, Central African Republic Outpatient clinic CS Conv Women with GUD ELISA 25 100 
Mbopi-keou, 2000 63 – Central African Republic Outpatient clinic CS Conv Women in an STD clinic ELISA 300 99.0 
Morse, 1997 64 1993–94 Lesotho Hospital CS Conv Men with GUD WB 47 91.5 
Morse, 1997 64 1993–94 Lesotho Hospital CS Conv Women with GUD WB 16 100 
Phipps, 2016 65 2011–12 Uganda Hospital CS Conv Men with HSV-2 WB 11 91.0 
Phipps, 2016 65 2011–12 Uganda Hospital CS Conv Women with HSV-2 WB 28 100 
Suntoke, 2009 66 2002–06 Uganda Outpatient clinic CS Conv Patients with GUD WB 91 88.0 
Tedla, 2011 60 2002 Ethiopia Community CC a Conv Patients with schizophrenia ELISA 216 98.6 
Tedla, 2011 60 2002 Ethiopia Community CC a Conv Patients with bipolar disorder ELISA 199 96.0 
Other populations ( n = 10) 
Ghebrekian, 1999 45 1995–95 Eritrea Outpatient clinic CS Conv Female sex workers ELISA 107 89.0 
Gwanzura, 1998 51 – Zimbabwe Community CS Conv HIV positive men WB 224 100 
Hogrefe, 2002 52 – Kenya Outpatient clinic RCT b RS HIV positive and HIV negative women WB 235 95.0 
LeGoff, 2010 67 – Central African Republic Outpatient clinic CS Conv HIV positive patients ELISA 51 90.2 
Morse, 1997 64 1993–94 Lesotho Hospital CS Conv HIV positive men WB 21 100 
Morse, 1997 64 1993–94 Lesotho Hospital CS Conv HIV positive women WB 15 93.3 
Mostad, 2000 68 1994–96 Kenya Outpatient clinic CS Conv HIV positive women EIA 314 94.3 
Perti, 2014 59 – South Africa Hospital CS Conv HIV positive women WB 132 96.2 
Phipps, 2016 65 2011–12 Uganda Hospital CS Conv HIV positive men WB 20 100 
Phipps, 2016 65 2011–12 Uganda Hospital CS Conv HIV positive women WB 34 91.0 
a The original study design of the study is case-control. The included seroprevalence measures are those for each of cases and controls, separately. The population type classiﬁcation was assigned based on the actual population 
type for each of cases and controls, separately. 
b The original study design of the study is randomized clinical trial. The included seroprevalence measures are those for the baseline measures at the onset of the trial, before start of follow-up. 
Abbreviations: Conv = Convenience, CS = Cross-sectional, CC = Case-control, ELISA = Enzyme-linked immunosorbent type-speciﬁc assay, GUD = Genital ulcer disease, HIV = Human immunodeﬁciency virus, HSV-1 = Herpes simplex 
virus type 1, MSC = Multistage cluster sampling, NAb = Neutralizing antibody, RCT = Randomized-controlled trial, RS = Random sampling, STD = Sexually transmitted disease, WB = Western blot. 
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Table 2 
Pooled mean estimates for HSV-1 seroprevalence in different populations in Africa. 
Population type Outcome 
measures 
Samples HSV-1 seroprevalence Pooled mean HSV-1 
seroprevalence 
Heterogeneity measures 
Total n Total N Range Median Mean (95% CI) Q a ( p -value) I ²b (%) (95% CI) Prediction c Interval (%) 
Healthy general populations 
Children 16 1052 6.9–97.0 71.5 69.2 (56.1–81.0) 286.0 ( p < 0.0001) 94.8 (92.8–96.2) 14.2–100 
Adults 28 9554 18.0–100 94.3 95.5 (93.6–97.1) 235.7 ( p < 0.0001) 88.5 (84.6–91.5) 84.2–100 
Age-mixed 1 d 100 – – 84.0 (75.3–90.7) – – –
All healthy general 
populations 
45 10,706 6.9–100 90.3 88.1 (84.3–91.4) 995 ( p < 0.0001) 95.6 (94.7–96.3) 57.6–100 
Clinical populations 
Children 2 d 57 44.0–51.0 47.5 49.1 (35.1–63.2) – – –
Adults 12 2268 88.0–100 98.4 97.8 (96.1–99.2) 36.7 ( p < 0.0001) 70.1 (45.9–83.4) 91.1–100 
All clinical populations 14 2321 44.0–100 97.1 94.8 (90.8–97.9) 123.5 ( p < 0.0001) 89.5 (84.1–93.0) 74.5–100 
Other populations 
HIV positive patients 8 811 90.2–100 95.3 97.1 (92.8–99.7) 34.2 ( p < 0.0001) 79.5 (60.1–89.5) 79.0–98.7 
Female sex workers 1 d 107 – – 98.0 (81.2–94.1) – – –
Mixed healthy/clinical 
adult populations 
1 d 235 – – 95.0 (91.2–97.3) – – –
Age group 
≤5 years 9 502 6.9–73.0 51.0 44.4 (29.9–59.3) 86.8 ( p < 0.0001) 90.8 (84.8–94.4) 2.9–91.6 
5–15 years 4 279 78.6–90.3 84.6 85.6 (81.0–89.6) 1.3 ( p = 0.7364) 0.0 (0.0–63.8) 74.9–93.8 
16–25 years 3 200 92.0–94.9 93.5 93.3 (89.2–96.6) 0.2 ( p = 0.9259) 0.0 (0.0–0.0) 56.0–100 
> 25 years 4 145 84.3–100 95.2 93.8 (84.6–99.4) 6.8 ( p = 0.0780) 56.0 (0.0–85.4) 46.3–100 
Age bracket 
All children 18 1105 6.9–97.0 70.0 67.1 (54.7–78.5) 297.7 ( p < 0.0001) 94.3 (92.3–95.8) 13.6–100 
All adults 50 12,975 18.0–100 95.0 96.2 (95.0–97.3) 341.2 ( p < 0.0001) 85.6 (81.9–88.6) 86.6–100 
All age-mixed 1 d 100 – – 84.0 (75.3–90.7) – – –
All studies 69 14,180 6.9–100 93.0 90.8 (88.2–93.0) 1213.3 ( p < 0.0001) 94.4 (93.5–95.2) 65.6–100 
a Q: The Cochran’s Q statistic is a measure assessing the existence of heterogeneity in pooled outcome measures, here HSV-1 seroprevalence. 
b I 2 : A measure that assesses the magnitude of between-study variation that is due to differences in seroprevalence across studies rather than chance. 
c Prediction interval: A measure that estimates the distribution (the 95% interval) of true seroprevalence around the estimated pooled mean. 
d No meta-analysis was done due to small number of studies ( n < 3). 
Abbreviations: CI = Conﬁdence interval, HIV = Human immunodeﬁciency virus, HSV-1 = Herpes simplex virus type 1. 
Quality assessment 
In light of established limitations in the sensitivity and speci- 
ﬁcity of diagnostic assays in assessing HSV-1 serology, 34,35 the 
quality of the diagnostic method in each study was assessed 
in consultation with an expert advisor, Professor Rhoda Ashley- 
Morrow, University of Washington, Seattle. 
The quality of studies was further evaluated using the Cochrane 
approach for the risk of bias (ROB) assessment and precision as- 
sessment, for each included seroprevalence measure. 22 Low versus 
high ROB was determined using two domains: sampling methodol- 
ogy (probability-based sampling versus non-probability sampling), 
and response rate ( ≥80% versus > 80%). Studies with missing in- 
formation for a speciﬁc domain were classiﬁed as having “unclear”
ROB for that domain. Low versus high precision assessment was 
based on the number of subjects tested in each study ( < 100 ver- 
sus ≥100). 
Results 
Search results and scope of evidence 
Fig. 1 shows the study selection process. 23 The search identi- 
ﬁed 7046 citations: 1583 from PubMed, 4768 from Embase, and 
695 from African Index Medicus. After removing duplicates and ti- 
tle and abstract screening, 605 reports were considered relevant or 
potentially relevant. Full-text screening yielded 37 reports meeting 
the inclusion criteria. No additional data were identiﬁed by screen- 
ing the bibliographies of relevant reports and reviews. 
Extracted outcome measures included: 43 overall HSV-1 sero- 
prevalence measures including 69 stratiﬁed seroprevalence mea- 
sures, 18 proportions of HSV-1 viral detection in GUD, and eight 
proportions of HSV-1 viral detection in genital herpes. 
Seroprevalence overview 
Table 1 describes the included HSV-1 stratiﬁed seroprevalence 
measures. Most measures were based on convenience sampling 
(number of studies ( n ) = 67; 97.1%), and were conducted prior to 
2010 ( n = 52; 75.4%). Across all measures ( n = 69), seroprevalence 
ranged between 6.9% and 100% with a median of 93.0% ( Table 2 ). 
In healthy general populations, seroprevalence ranged, for chil- 
dren ( n = 16), between 6.9% and 97.0% with a median of 71.5%, 
and for adults ( n = 28), between 18.0% and 100% with a median of 
94.3%. In clinical populations, seroprevalence ranged, for children 
( n = 2), between 44.0% and 51.0% with a median of 47.5%, and for 
adults ( n = 12), between 88.0% and 100% with a median of 98.4%. 
Summaries for further populations (or subpopulation categories) 
are shown in Table 2 . 
Pooled mean estimates for HSV-1 seroprevalence 
Table 2 shows the pooled mean estimates for HSV-1 seropreva- 
lence overall, in different populations, and across age groups. The 
overall pooled mean seroprevalence (across all data points, n = 69) 
was 90.8% (95% conﬁdence interval (CI): 88.2–93.0%). 
In healthy general populations, the pooled mean seropreva- 
lence was 69.2% ( n = 16; 95% CI: 56.1–81.0%) in children, and 95.5% 
( n = 28; 95% CI: 93.6–97.1%) in adults. In clinical populations, the 
pooled mean seroprevalence was 49.1% ( n = 2; 95% CI: 35.1–63.2%) 
in children, and 97.8% ( n = 12; 95% CI: 96.1–99.2%) in adults. 
Across age groups, the pooled mean seroprevalence was lowest 
at 44.4% ( n = 9; 95% CI: 29.9–59.3%) in those ≤5 years old, followed 
by 85.6% ( n = 4; 95% CI: 81.0–89.6%) in those 6–15 years old, 93.3% 
( n = 3; 95% CI: 89.2–96.6%) in those 16–25 years old, and 93.8% 
( n = 4; 95% CI: 84.6–99.4%) in those > 25 years old. 
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Table 3 
Univariable and multivariable meta-regression analyses for HSV-1 seroprevalence in Africa. 
Outcome measures Samples Univariable analysis Multivariable analysis 
Total n Total N RR (95%CI) p -value Adjusted R 2 (%) Model 1 a Model 2 b 
ARR (95%CI) p -value ARR (95%CI) p -value 
Age bracket Children 18 1105 1.0 – 1.0 – – –
Adults 50 12,975 1.2 (1.1–1.3) 0.000 1.1 (1.0–1.2) 0.005 – –
Age-mixed 1 100 1.1 (0.8–1.4) 0.565 62.4 1.0 (0.8–1.2) 0.956 – –
Age group ≤5 9 502 1.0 – – – 1.0 –
6–15 4 279 1.5 (1.3–1.7) 0.000 – – 1.4 (1.2–1.6) 0.000 
15–25 3 200 1.6 (1.4–1.9) 0.000 – – 1.5 (1.3–1.7) 0.000 
> 25 4 145 1.6 (1.4–1.9) 0.000 – – 1.5 (1.3–1.7) 0.000 
Mixed 49 12,639 1.7 (1.5–1.9) 0.000 78.8 – – 1.5 (1.3–1.7) 0.000 
Assay type Western blot 39 5271 1.0 – 1.0 – 1.0 –
ELISA 21 8422 1.0 (0.9–1.0) 0.131 1.0 (0.9–1.0) 0.479 1.0 (0.9–1.0) 0.429 
NAb 9 487 0.7 (0.6–0.8) 0.000 62.7 e 0.7 (0.6–0.9) 0.002 0.8 (0.7–0.9) 0.000 
Country’s 
income 
LIC 46 6226 1.0 1.0 – 1.0 –
LMIC 16 1235 0.9 (0.8–1.0) 0.025 1.0 (0.9–1.1) 0.753 1.0 (1.0–1.1) 0.601 
UMIC 5 1698 1.0 (0.9–1.2) 0.521 1.0 (0.9–1.1) 0.945 1.0 (1.0–1.1) 0.945 
Mixed 2 5021 1.1 (0.8–1.3) 0.600 0.0 1.0 (0.9–1.1) 0.770 1.0 (0.9–1.1) 0.715 
Population 
type 
Healthy general 
populations 
45 10,706 1.0 – – – – –
Clinical 
populations 
14 2321 1.1 (1.0–1.2) 0.214 – – – –
Other populations 10 1153 1.1 (1.0–1.2) 0.211 6.0 – – – –
Response 
rate 
≥80 29 9306 1.0 – – – – –
Otherwise c 40 4874 0.9 (0.9–1.0) 0.284 0.0 – – – –
Sample size d < 100 26 1164 1.0 – – – – –
≥100 43 13,016 1.0 (0.9–1.1) 0.637 0.0 – – – –
Sampling 
methodology 
Non-probability 63 12,190 1.0 – – – – –
Probability-based 6 1990 1.1 (0.9–1.2) 0.320 0.0 – – – –
Sex Female 18 7510 1.0 – 1.0 – 1.0 
Male 13 2422 1.0 (0.9–1.1) 0.904 1.0 (0.9–1.1) 0.948 1.0 (1.0–1.0) 0.755 
Mixed 38 4248 0.9 (0.8–1.0) 0.014 20.3 f 1.0 (0.9–1.1) 0.849 1.0 (0.9–1.0) 0.744 
Year of data collection 69 14,180 1.0 (1.0–1.0) 0.002 4.3 – – – –
Year of publication 69 14,180 1.0 (1.0–1.0) 0.001 12.4 1.0 (1.0–1.0) 0.714 1.0 (1.0–1.0) 0.575 
a Variance explained by the ﬁnal multivariable model 1 (adjusted R 2 ) = 68.3%. 
b Variance explained by the ﬁnal multivariable model 2 (adjusted R 2 ) = 84.9%. 
c Otherwise indicates either response rate not included in the report or response rate was < 80%. 
d Sample size denotes the sample size of each study population found in the original publication. 
e The high adjusted R 2 was investigated and found to be due to confounding with age. Nearly all studies that used NAb were conducted among children. 
f The high adjusted R 2 was investigated and found to be due to confounding with age. All studies among children were mixed including both females and males. 
Abbreviations: ARR = Adjusted risk ratio, ELISA = Enzyme-linked immunosorbent type-speciﬁc assay, CI = Conﬁdence interval, HSV-1 = Herpes simplex virus type 1, LIC = Low- 
income country, LMIC = Lower-middle-income country, NAb = Neutralizing antibody, RR = Risk ratio, UMIC = Upper-middle-income country. 
Forest plots for the two key meta-analyses (all children and 
all adults) can be found in Supplementary Fig. 1. Most meta- 
analyses showed strong evidence for heterogeneity in seropreva- 
lence ( p < 0.1; Table 2 ). Heterogeneity was mainly due to true 
differences in seroprevalence rather than chance (I ²> 50%). The 
wide prediction intervals conﬁrmed this heterogeneity. The meta- 
regressions below investigated the sources of this heterogeneity. 
Predictors of HSV-1 seroprevalence and sources of between-study 
heterogeneity 
Results of the univariable and multivariable meta-regressions 
are in Table 3 . Age bracket, age group, assay type, country’s 
income, sex, year of data collection, and year of publication qual- 
iﬁed for inclusion in the multivariable analyses ( p < 0.1). Popu- 
lation type, response rate, sample size, and sampling methodol- 
ogy were not associated with seroprevalence ( p > 0.1). Age was 
(by far) the variable that explained most of the heterogeneity in 
seroprevalence—age bracket explained 62.4% of the variation, and 
age group explained 78.8% of the variation. 
Two multivariable models were conducted to investigate sep- 
arately the effects of age bracket versus age group, as these two 
age variables are not independent. Moreover, because also of lack 
of independence, only year of publication variable (as it has more 
complete data) was included in the multivariable models, instead 
of the year of data collection variable. 
The ﬁrst model, including age bracket, explained 68.3% of sero- 
prevalence variation. Compared to children, seroprevalence was 
1.1-fold (95% CI: 1.0–1.2) higher in adults. Compared to Western 
blot, seroprevalence was 0.7-fold (95% CI: 0.6–0.9) lower when 
measured using a NAb assay. No association with each of country’s 
income, sex, and year of publication was found ( p > 0.05). 
The second model, including age group, explained 84.9% of 
seroprevalence variation, with comparable results to the ﬁrst 
model. Compared to those ≤5 years of age, seroprevalence was 
1.4-fold (95% CI: 1.2–1.6) higher in those 6–15 years old, and ex- 
actly (remarkably) 1.5-fold (95% CI: 1.3–1.7) higher in each of the 
remaining age groups. 
HSV-1 viral detection in genital ulcer disease and in genital herpes 
Table 4 describes the extracted measures for the proportions of 
HSV-1 viral detection in GUD ( n = 18) and in genital herpes ( n = 8). 
In GUD cases, the proportion ranged between 0.0% to 6.0% with 
a median of 0.0%, while the pooled mean proportion was 0.4% 
(95% CI: 0.0–1.5%; Table 5 ). In genital herpes cases, the proportion 
ranged between 0.0% and 5.0% with a median of 2.4%, while the 
pooled mean proportion was 1.2% (95% CI: 0.0–4.0%; Table 5 ). For- 
est plots are shown in Supplementary Fig. 2. There was strong ev- 
idence for heterogeneity, but the prediction intervals were narrow, 
aﬃrming very small proportions of HSV-1 detection in both GUD 
and genital herpes. 
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Table 4 
Studies from Africa reporting proportion of HSV-1 viral detection in clinically-diagnosed genital ulcer disease (GUD), or proportion of HSV-1 viral detection in clinically- 
diagnosed genital herpes. 
Author, year Year(s) of 
data 
collection 
Country Study site Study 
design 
Sampling 
methodology 
Population HSV-1 
biological 
assay 
Sample size Proportion of 
HSV-1 
detection (%) 
HSV-1 detection in clinically-diagnosed GUD ( n = 18) 
Brankin, 2009 69 − Uganda Outpatient clinic CS Conv HIV positive women PCR 16 0.0 
Brankin, 2009 69 − Uganda Outpatient clinic CS Conv HIV negative women PCR 24 0.0 
Chen, 2000 61 – South Africa Outpatient clinic CS Conv Men attending different STI 
clinics 
PCR 538 0.0 
Gray, 2009 70 – Uganda Outpatient clinic CS Conv Circumcised men PCR 25 0.0 
Gray, 2009 70 – Uganda Outpatient clinic CS Conv Uncircumcised Men PCR 56 0.0 
Kamya, 1995 71 1990–91 Uganda Outpatient clinic CS Conv Patients with GUD IFA 98 3.1 
Kularatne, 2018 72 2007–15 South Africa Outpatient clinic CS Conv Patients attending a health 
care center 
PCR 771 0.0 
Lewis, 2012 73 2005–06 South Africa Outpatient clinic RCT a Conv Men with GUD PCR 610 3.1 
Makasa, 2012 74 2010–10 Zambia Outpatient clinic CS Conv Men with GUD PCR 100 0.0 
Makasa, 2012 74 2010–10 Zambia Outpatient clinic CS Conv Women with GUD PCR 100 1.0 
Mungati, 2018 75 2014–15 Zimbabwe Outpatient clinic CS Conv Patients attending different 
STI clinics 
PCR 200 0.5 
Mwansasu, 2002 76 2002 Tanzania Outpatient clinic CS Conv Men attending a STI clinic PCR 51 0.0 
Mwansasu, 2002 76 2002 Tanzania Outpatient clinic CS Conv Women attending a STI 
clinic 
PCR 19 0.0 
Nilsen, 2007 77 1999–01 Tanzania Outpatient clinic CS Conv Patients with GUD PCR 301 6.0 
Paz-Bailey, 2005 78 2001–02 Bostwana Outpatient clinic CS Conv Patients with GUD PCR 137 0.0 
Suntoke, 2009 66 2002–06 Uganda Outpatient clinic CS Conv Men with GUD PCR 50 6.0 
Suntoke, 2009 66 2002–06 Uganda Outpatient clinic CS Conv Women with GUD PCR 50 0.0 
Vandepitte, 2011 79 2008–09 Uganda Outpatient clinic CS Conv Female sex workers with 
GUD 
PCR 62 0.0 
HSV-1 detection in clinically-diagnosed genital herpes ( n = 8) 
Chen, 2000 61 – South Africa Outpatient clinic CS Conv Men attending different STI 
clinics 
PCR 193 0.0 
Kularatne, 2018 72 2007–15 South Africa Outpatient clinic CS Conv Patients attending a health 
care center 
PCR 468 0.0 
Lai, 2003 80 1993–94 South Africa Outpatient clinic CS Conv Men with genital herpes PCR 14 0.0 
Lai, 2003 80 1998 South Africa Outpatient clinic CS Conv Men with genital herpes PCR 57 3.5 
Lewis, 2012 73 2005–06 South Africa Outpatient clinic RCT a Conv Men with genital herpes PCR 448 4.2 
Morse, 1997 64 1993–94 Lesotho Hospital CS Conv Patients with genital herpes PCR 20 5.0 
Mungati, 2018 75 2014–15 Zimbabwe Outpatient clinic CS Conv Patients attending different 
STI clinics 
PCR 77 1.3 
Suntoke, 2009 66 2002–06 Uganda Outpatient clinic CS Conv Patients with genital herpes PCR 65 4.6 
a The original study design of the study is randomized clinical trial. The included proportion measures are those for the baseline measures at the onset of the trial, before 
start of follow up. 
Abbreviations: Conv = Convenience, CS = Cross sectional, GUD = Genital ulcer disease, HIV = Human immunodeﬁciency virus, HSV-1 = Herpes simplex virus type 1, 
IFA = Immunoﬂuorescence, PCR = Polymerase chain reaction, RCT = Randomized-controlled trial, STI = Sexually transmitted infections. 
Table 5 
Pooled proportions in Africa of HSV-1 viral detection in clinically-diagnosed genital ulcer disease (GUD), and in clinically-diagnosed genital herpes. 
Population type Outcome 
measures 
Samples Proportion of HSV-1 
detection (%) 
Pooled proportion of 
HSV-1 detection (%) 
Heterogeneity measures 
Total n Total N Range Median Mean (95% CI) Q a ( p -value) I ²b (%) (95% CI) Prediction Interval c (%) 
Patients with GUD 18 3208 0.0–6.0 0.0 0.4 (0.0–1.5) 89.1 ( p < 0.0001) 80.9 (70.8–87.6) 0.0–7.1 
Patients with 
genital herpes 
8 1342 0.0–5.0 2.4 1.2 (0.0–4.0) 44.4 ( p < 0.0001) 84.2 (70.7–91.5) 0.0–14.5 
a Q: The Cochran’s Q statistic is a measure assessing the existence of heterogeneity in pooled outcome measures, here proportions of HSV-1 viral detection. 
b I 2 : A measure that assesses the magnitude of between-study variation that is due to differences in proportions of HSV-1 viral detection across studies rather than chance. 
c Prediction interval: A measure used here to estimate the distribution (the 95% interval) of true proportion of HSV-1 viral detection around the estimated pooled mean. 
Abbreviations: CI = Conﬁdence interval, GUD = Genital ulcer disease, HSV-1 = Herpes simplex virus type 1. 
Quality assessment 
Most seroprevalence studies (51.2%) used Western blot, the 
gold standard for HSV-1 serology, 36 as the diagnosis method. 
Summary of the results of the quality assessments are in Sup- 
plementary Table 2. Most studies had high precision (58.1%), but 
also high ROB in the sampling methodology domain (86.1%). For 
the response rate domain, 41.9% of studies had low ROB while, 
remaining studies (58.1%) had unclear ROB. In view of the results 
of the meta-regressions ( Table 3 ), with the response rate, sample 
size, and sampling methodology not being associated with HSV-1 
seroprevalence, the overall evidence appears to be of reasonable 
quality. 
Discussion 
A detailed and systematic assessment of HSV-1 epidemiology in 
Africa was conducted. The results demonstrate that HSV-1 is uni- 
versally prevalent, with nearly every person acquiring the infection 
by age 15 ( Tables 2 and 3 ). Strikingly, exposure to the infection 
appears to be immensely homogenous for the entire population, 
regardless of sex, country’s income, or health status ( Table 3 ). Even 
factors such as response rate, sampling methodology, or sample 
size, which often introduce bias in prevalence studies for different 
diseases, 37,38 did not affect the observed seroprevalence ( Table 3 ). 
There was also no evidence for any change in seroprevalence over 
the last few decades ( Table 3 ). 
Please cite this article as: M. Harfouche, H. Chemaitelly and L.J. Abu-Raddad, Herpes simplex virus type 1 epidemiology in Africa: Sys- 
tematic review, meta-analyses, and meta-regressions, Journal of Infection, https://doi.org/10.1016/j.jinf.2019.07.012 
M. Harfouche, H. Chemaitelly and L.J. Abu-Raddad / Journal of Infection xxx (xxxx) xxx 9 
ARTICLE IN PRESS 
JID: YJINF [m5G; August 7, 2019;13:48 ] 
Seroprevalence in Africa was found to be much higher ( Table 2 ) 
than that estimated for the global population at 67%. 1 HSV-1 sero- 
prevalence is also well documented in different Western countries, 
with levels of only about 50%. 7–13 , 39,40 Though HSV-1 seropreva- 
lence was found to be high in Asia, the Middle East and North 
Africa (MENA), and Latin America and the Caribbean in three re- 
cent systematic reviews, 15,51,41 it was not as high as that in Africa, 
particularly among younger adults. Moreover, no variation in sero- 
prevalence by country, or by country’s income level, was found in 
Africa ( Tables 1 and 3 ). This stands in contrast to observed varia- 
tions in other regions, 15,41 that are consistent with an association 
between HSV-1 infection and lower socio-economic status. 39,42 
Though seroprevalence is declining in developed coun- 
tries, 7–13 , 39,40 such as the U.S.A 40,43 and Japan, 15,44 with the 
improvements in living and hygiene conditions, 40 such trend is 
not seen in Africa ( Table 3 ). Africa continues to exhibit what can 
be labelled as the “historical pattern” of HSV-1 infection, whereby 
nearly every person acquires the infection in early childhood, 
through oral-to-oral transmission, and where homogeneity in 
exposure dominates, in contrast to the increasingly heterogonous 
and variable exposure elsewhere. 7–13 , 15 , 16,39–41 
Only age was a strong predictor of seroprevalence in Africa 
( Table 3 ). Remarkably, it explained also nearly 80% of seropreva- 
lence variation—hardly any other factor was needed to explain this 
variation. This is to be contrasted with Asia, 15 MENA, 41 and Latin 
America and the Caribbean 16 where age explained only 34% 48%, 
and 54% of seroprevalence variation, respectively. This further af- 
ﬁrms the universality and homogeneity of the infection in Africa—
it is just a question of cumulative person-time of exposure be- 
fore nearly every person acquires the infection. Seroprevalence in 
Africa grows very rapidly following birth ( Tables 2 and 3 ), high- 
lighting the strong force of infection in the community. By age 15, 
seroprevalence plateaus at > 90%, and is independent of age for all 
older age groups, simply because seroprevalence reached its satu- 
ration level. 
A key ﬁnding of this study is the extremely low detection of 
HSV-1 in both GUD and genital herpes ( Tables 4 and 5 ), in contrast 
to Western countries, Asia, and Latin America and the Caribbean. 
In multiple Western countries, HSV-1 is already the primary cause 
of genital herpes, 2 , 17–21 and in Asia and Latin america and the 
Caribbean, about 20% of genital herpes is attributed to HSV-1. 15,17 
The low detection in Africa is probably best explained by most per- 
sons reaching sexual debut already infected, thus with protective 
antibodies against genital acquisition. The observed epidemiolog- 
ical transition towards less oral acquisition and more genital ac- 
quisition, that is seen in multiple countries, 2,14,21 appears far from 
being realized in Africa. 
This epidemiological assessment is limited by the quantity, 
quality, and representativeness of included studies. Most data were 
from the more populous African countries, and 31 (mostly small) 
countries had no identiﬁable data. There was evidence for a lower 
seroprevalence whenever a NAb assay was used as the diagnos- 
tic method ( Table 3 )—this may have underestimated the calculated 
pooled mean seroprevalence. Notably, 51.2% of the studies used 
Western blot, the gold standard for HSV-1 serological diagnosis, 36 
in contrast to other regions where seroprevalence is most often 
assessed using ELISA. 15,41 This is probably explained by the well- 
funded and high-quality international studies that were conducted 
in Africa to investigate HSV-1 infection, as part of the expansion of 
HIV research in this continent. 
Conclusions 
Africa continues to exhibit the “historical pattern” of HSV-1 in- 
fection, with nearly every person acquiring the infection in child- 
hood through oral-to-oral transmission. The infection is universally 
prevalent, at higher levels than other regions, with no evidence 
for declines in seroprevalence in recent decades. Exposure to HSV- 
1 is homogenous in the population at large, only one factor, age, 
was needed to explain most of the variation in seroprevalence. 
Sexual oral-to-genital and genital-to-genital transmission appear to 
be very limited—HSV-1 viral detection was extremely low in both 
GUD and genital herpes. These ﬁndings suggest a signiﬁcant bur- 
den of oral herpes and related disease sequelae that remains to be 
quantiﬁed and tackled in this region. The ﬁndings also support the 
need for an HSV-1 vaccine to control transmission and prevent its 
disease burden. 
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